公开(公告)号：US20200291463A1

公开(公告)日：2020-09-17

申请号：US16809674

申请日：2020-03-05

Applicant: Duke University

Inventor： Tuan Vo-Dinh ,  Hsin-Neng Wang ,  Andrew Fales

IPC: C12Q1/6825 ,  A61K31/713

Abstract: Plasmonics-active nanoprobes are provided for detection of target biomolecules including nucleic acids, proteins, and small molecules. The nucleic acids that can be detected include RNA, DNA, mRNA, microRNA, and small nucleotide polymorphisms (SNPs). The nanoproprobes can be used in vito in sensitive detection methods for diagnosis of diseases and disorders including cancer. Multiplexing can be performed using the nanoprobes such that multiple targets can be detected simultaneously in a single sample. The methods of use of the nanoprobes include detection by a visible color change. The nanoprobes can be used in vivo for treatment of undesireable cells in a subject.

公开(公告)号：US10300299B2

公开(公告)日：2019-05-28

申请号：US15786046

申请日：2017-10-17

Applicant: Immunolight, LLC ,  Duke University

Inventor： Frederic A. Bourke, Jr. ,  Tuan Vo-Dinh

IPC: A61K41/00 ,  A61N5/06 ,  A61K31/7056 ,  A61K47/55 ,  A61K31/4427 ,  A61K31/7052

Abstract: The present invention relates to methods for treating cell proliferation disorders comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder; and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes; a kit and a computer implemented system for performing the method; a pharmaceutical composition useful in the method; and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US20180133319A1

公开(公告)日：2018-05-17

申请号：US15852598

申请日：2017-12-22

Applicant: Duke University

Inventor： Tuan Vo-Dinh ,  Brant A. Inman ,  Paolo Maccarini ,  Greg Palmer ,  Yang Liu ,  Douglas Weitzel

IPC: A61K41/00 ,  A61P35/00 ,  A61P35/04 ,  A61K9/51 ,  A61K33/24 ,  A61K39/395 ,  A61K9/00 ,  A61K47/69 ,  A61P35/02 ,  A61N5/06 ,  A61N1/40 ,  A61N5/02 ,  A61B18/20 ,  A61B18/14 ,  A61B18/18

CPC classification number: A61K41/0052 ,  A61B18/14 ,  A61B18/1815 ,  A61B18/20 ,  A61B2018/00577 ,  A61B2018/1807 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/51 ,  A61K33/24 ,  A61K39/39558 ,  A61K47/6929 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/572 ,  A61N1/403 ,  A61N5/00 ,  A61N5/025 ,  A61N5/062 ,  A61N5/0625 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/067 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  B22F1/0022 ,  B22F2999/00 ,  C07K16/2827 ,  B22F1/0062 ,  B22F2001/0029 ,  B22F2001/0033 ,  B22F2001/0037

Abstract: The presently disclosed subject matter is directed to a method of treating cancer, such as (but not limited to) metastatic bladder and breast cancer. The disclosed method comprises using two treatment modalities to synergistically treat primary and secondary tumor cells in a subject. The first element of the method comprises administering a therapeutically effective amount of a plasmonics-active metal nanoparticle to a subject comprising a primary cancer and a distant metastatic site, wherein the nanoparticle concentrates at the primary cancer. The method further comprises exposing the subject to photon radiation at the site of the primary cancer. The second element of the disclosed method comprises administering a therapeutically effective amount of an immune checkpoint modulator to the subject. The synergistic combination provides a rapid, safe, and effective treatment of local and distant lesions, better than each modality alone.

公开(公告)号：US09789154B1

公开(公告)日：2017-10-17

申请号：US13888226

申请日：2013-05-06

Applicant: Duke University

Inventor： Tuan Vo-Dinh ,  Hsiangkuo Yuan ,  Andrew Fales

IPC: A61K38/02 ,  A61K49/00

CPC classification number: A61K38/02 ,  A61K41/0066 ,  A61K41/0071 ,  A61K47/62 ,  A61K47/6923 ,  A61K49/0065

Abstract: Plasmonics-active metal nanostars are provided that can be used for treating and detecting cells in a subject. The modes of treatment include a photo-activated drug, which is activated by the photo-response of the nanostar to electromagnetic stimulation; a thermally-activated drug, which is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which may directly or indirectly cause the death of an undesirable cell. Uptake of nanostars by undesirable cells may also aid in detection, by enhancing contrast or otherwise transforming electromagnetic stimulation during imaging.

公开(公告)号：US20170173350A1

公开(公告)日：2017-06-22

申请号：US15443656

申请日：2017-02-27

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Frederic Avery Bourke, JR. ,  Tuan Vo-Dinh

IPC: A61N5/06 ,  C08J7/18 ,  C08J3/28 ,  C08J3/24 ,  B01J19/12 ,  A61L2/10 ,  A61L2/00 ,  C02F1/30 ,  C02F1/32 ,  C02F1/72 ,  A23L3/26 ,  A23L3/28 ,  A23L2/50 ,  G21K5/00 ,  G02B5/00 ,  A61N5/10 ,  A61K41/00

CPC classification number: B01J19/123 ,  A23L2/50 ,  A23L3/26 ,  A23L3/263 ,  A23L3/28 ,  A23L5/32 ,  A23V2002/00 ,  A61K41/0057 ,  A61K41/0066 ,  A61L2/0011 ,  A61L2/0047 ,  A61L2/0076 ,  A61L2/082 ,  A61L2/088 ,  A61L2/10 ,  A61L2/16 ,  A61L2202/21 ,  A61L2202/22 ,  A61M1/3683 ,  A61N5/062 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1087 ,  A61N2005/1089 ,  A61N2005/1098 ,  B01J19/082 ,  B01J19/085 ,  B01J19/12 ,  B01J19/125 ,  B01J19/127 ,  B01J19/128 ,  B01J23/50 ,  B01J23/52 ,  B01J31/0275 ,  B01J31/2295 ,  B01J35/0006 ,  B01J35/0013 ,  B01J35/004 ,  B01J37/0072 ,  B01J37/0221 ,  B01J2219/0877 ,  B01J2219/0879 ,  B01J2219/0892 ,  B01J2219/1203 ,  B01J2231/005 ,  B01J2531/005 ,  B01J2531/008 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00 ,  C02F1/30 ,  C02F1/302 ,  C02F1/305 ,  C02F1/307 ,  C02F1/32 ,  C02F1/725 ,  C02F2305/10 ,  C08J3/24 ,  C08J3/28 ,  C08J7/18 ,  C08J2300/00 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  C09J2205/31 ,  C12H1/06 ,  G02B5/008 ,  G21K5/00 ,  Y02W10/37 ,  Y10S977/774 ,  Y10S977/777 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T156/10

Abstract: A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

公开(公告)号：US09630022B2

公开(公告)日：2017-04-25

申请号：US14165026

申请日：2014-01-27

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Frederic Avery Bourke, Jr. ,  Tuan Vo-Dinh

IPC: A61K9/00 ,  A61K31/00 ,  A61K33/00 ,  A61K41/00 ,  C08F2/50 ,  C08J3/28 ,  A61N5/10 ,  A23L3/26 ,  A61L2/00 ,  B01J19/08 ,  B01J19/12 ,  C02F1/30 ,  C02F1/72 ,  A61L2/08 ,  A61L2/10 ,  A61L2/16 ,  G21K5/00 ,  C02F1/32 ,  A61N5/06 ,  A23L5/30 ,  B82Y20/00

CPC classification number: A61N5/10 ,  A23L2/50 ,  A23L3/26 ,  A23L3/263 ,  A23L3/28 ,  A23L5/32 ,  A23V2002/00 ,  A61K41/0057 ,  A61K41/0066 ,  A61L2/0011 ,  A61L2/0047 ,  A61L2/0076 ,  A61L2/082 ,  A61L2/088 ,  A61L2/10 ,  A61L2/16 ,  A61L2202/21 ,  A61L2202/22 ,  A61M1/3683 ,  A61N5/062 ,  A61N5/0624 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1087 ,  A61N2005/1089 ,  A61N2005/1098 ,  B01J19/082 ,  B01J19/085 ,  B01J19/12 ,  B01J19/123 ,  B01J19/125 ,  B01J19/127 ,  B01J19/128 ,  B01J23/50 ,  B01J23/52 ,  B01J31/0275 ,  B01J31/2295 ,  B01J35/0006 ,  B01J35/0013 ,  B01J35/004 ,  B01J37/0072 ,  B01J37/0221 ,  B01J2219/0877 ,  B01J2219/0879 ,  B01J2219/0892 ,  B01J2219/1203 ,  B01J2231/005 ,  B01J2531/005 ,  B01J2531/008 ,  B82Y20/00 ,  B82Y30/00 ,  B82Y40/00 ,  C02F1/30 ,  C02F1/302 ,  C02F1/305 ,  C02F1/307 ,  C02F1/32 ,  C02F1/725 ,  C02F2305/10 ,  C08J3/24 ,  C08J3/28 ,  C08J7/18 ,  C08J2300/00 ,  C09D201/00 ,  C09J5/00 ,  C09J201/00 ,  C09J2205/31 ,  C12H1/06 ,  G02B5/008 ,  G21K5/00 ,  Y02W10/37 ,  Y10S977/774 ,  Y10S977/777 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T156/10

Abstract: A method and a system for producing a change in a medium disposed in an artificial container. The method places in a vicinity of the medium at least one of a plasmonics agent and an energy modulation agent. The method applies an initiation energy through the artificial container to the medium. The initiation energy interacts with the plasmonics agent or the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the plasmonics agent or the energy modulation agent.

公开(公告)号：US20220233628A1

公开(公告)日：2022-07-28

申请号：US17712479

申请日：2022-04-04

Applicant: Duke University

Inventor： Tuan Vo-Dinh ,  Hsiangkuo Yuan ,  Andrew Fales

IPC: A61K38/02 ,  A61K49/00 ,  A61K41/00 ,  A61K47/62 ,  A61K47/69

Abstract: A plasmonics-active gold nanostar results from the following process: adding citrate stabilized gold seeds to a solution of tetrachloroauric acid (HAuCl4) under acidic conditions; and mixing a silver salt compound and a weak reducing agent simultaneously into the solution of HAuCl4 under conditions such that the plasmonics-active gold nanostar is produced. The plasmonics-active gold nanostar has a size of at least about 30 nm and up to about 80 nm, comprises a plasmon peak in the near-infrared region, comprises an optical label and a bioreceptor, and is a nucleic acid.

公开(公告)号：US11383098B2

公开(公告)日：2022-07-12

申请号：US16516463

申请日：2019-07-19

Applicant: Immunolight, LLC ,  Duke University

Inventor： Tuan Vo-Dinh ,  Jonathan P. Scaffidi ,  Venkata Gopal Reddy Chada ,  Benoit Lauly ,  Yan Zhang ,  Molly K. Gregas ,  Ian Nicholas Stanton ,  Joshua T. Stecher ,  Michael J. Therien ,  Frederic A. Bourke, Jr. ,  Harold Walder ,  Zak Fathi ,  Jennifer A. Ayres ,  Zhenyuan Zhang ,  Joseph H. Simmons ,  Stephen John Norton

IPC: A61N5/06 ,  A61K49/00 ,  A61N1/40 ,  A61N5/02 ,  A61B5/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61L2/00 ,  A61L2/08 ,  A61N5/067 ,  A61N5/10

Abstract: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ1, to generate a second wavelength λ2 of radiation having a higher energy than the first wavelength λ1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

公开(公告)号：US11324797B2

公开(公告)日：2022-05-10

申请号：US15785615

申请日：2017-10-17

Applicant: Duke University

Inventor： Tuan Vo-Dinh ,  Hsiangkuo Yuan ,  Andrew Fales

IPC: A61K38/02 ,  A61K49/00 ,  A61K41/00 ,  A61K47/62 ,  A61K47/69

Abstract: Plasmonics-active metal nanostars are provided that can be used for treating and detecting cells in a subject. The modes of treatment include a photo-activated drug, which is activated by the photo-response of the nanostar to electromagnetic stimulation; a thermally-activated drug, which is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which may directly or indirectly cause the death of an undesirable cell. Uptake of nanostars by undesirable cells may also aid in detection, by enhancing contrast or otherwise transforming electromagnetic stimulation during imaging.

公开(公告)号：US10384071B2

公开(公告)日：2019-08-20

申请号：US15247367

申请日：2016-08-25

Applicant: IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY

Inventor： Tuan Vo-Dinh ,  Jonathan P. Scaffidi ,  Venkata Gopal Reddy Chada ,  Benoit Lauly ,  Yan Zhang ,  Molly K. Gregas ,  Ian Nicholas Stanton ,  Joshua T. Stecher ,  Michael J. Therien ,  Frederic A. Bourke, Jr. ,  Harold Walder ,  Zak Fathi ,  Jennifer A. Ayres ,  Zhenyuan Zhang ,  Joseph H. Simmons ,  Stephen John Norton

IPC: A61N5/06 ,  A61K49/00 ,  A61N1/40 ,  A61N5/02 ,  A61B5/00 ,  A61B5/055 ,  A61B6/00 ,  A61K41/00 ,  A61M5/00 ,  A61N5/10 ,  A61L2/00 ,  A61L2/08 ,  A61N5/067

Abstract: System for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The system can be used in methods which can be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure.